Remi Barbier


Remi Barbier
Chairman of the Board, President & CEO
Pain Therapeutics

Remi Barbier

Remi Barbier is a life-long entrepreneur in the life sciences -- and is honored to have worked with visionary scientists for nearly 30 years. In 1998, Mr. Barbier founded Pain Therapeutics, Inc. (Nasdaq:PTIE). Pain Therapeutics is an early pioneer in the development of abuse-deterrent drugs and has discovered novel drug candidates to treat brain disorders, such as Alzheimer’s Disease, and other clinical indications. Before that, Mr. Barbier co-founded or helped grow several life sciences companies, including Exelixis Inc. (Nasdaq:EXEL), a genomics-based drug discovery company; ArQule (Nasdaq:ARQL), a chemistry company now focused on oncology drug development; and EnzyMed, a catalysis chemistry company acquired by Albany Molecular Research.
 
Mr. Barbier was previously awarded the Ernst & Young Entrepreneur of the Year Award in Silicon Valley. He is a named inventor on issued patents and patents pending in the life sciences. Over the years, he has been a member of the board of directors of public and private companies and trustee of The Carnegie Institute of Washington and the Santa Fe Institute, both non-profit, independent research institutes.
 
Mr. Barbier earned an undergraduate degree from Oberlin College and a master’s degree from The University of Chicago. He splits his time between San Francisco and Austin, TX, with his wife, two children and a slew of domestic animals.  His areas of interests are memory, brain entropy and complex adaptive systems…and biking.